Regulus Therapeutics Statistics
Share Statistics
Regulus Therapeutics has 65.50M shares outstanding. The number of shares has increased by 223.72% in one year.
| Shares Outstanding | 65.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 52.93M |
| Failed to Deliver (FTD) Shares | 4.21K |
| FTD / Avg. Volume | 1.16% |
Short Selling Information
The latest short interest is 1.69M, so 2.58% of the outstanding shares have been sold short.
| Short Interest | 1.69M |
| Short % of Shares Out | 2.58% |
| Short % of Float | 3.19% |
| Short Ratio (days to cover) | 4.24 |
Valuation Ratios
The PE ratio is -0.81 and the forward PE ratio is -1.29.
| PE Ratio | -0.81 |
| Forward PE | -1.29 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.15 |
| P/FCF Ratio | -0.89 |
| PEG Ratio | n/a |
Enterprise Valuation
Regulus Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.31 |
| Quick Ratio | 2.96 |
| Debt / Equity | 0.06 |
| Total Debt / Capitalization | 5.92 |
| Cash Flow / Debt | -20.07 |
| Interest Coverage | -51.5 |
Financial Efficiency
Return on equity (ROE) is -1.42% and return on capital (ROIC) is -131.96%.
| Return on Equity (ROE) | -1.42% |
| Return on Assets (ROA) | -0.98% |
| Return on Capital (ROIC) | -131.96% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -938.66K |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | 7.03 |
Taxes
| Income Tax | 1K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 15.33% in the last 52 weeks. The beta is 1.63, so Regulus Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.63 |
| 52-Week Price Change | 15.33% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 51.63 |
| Average Volume (20 Days) | 362.54K |
Income Statement
In the last 12 months, Regulus Therapeutics had revenue of $0 and earned -$30.04M in profits. Earnings per share was $-1.58.
| Revenue | 0 |
| Gross Profit | -21.15M |
| Operating Income | -31.11M |
| Net Income | -30.04M |
| EBITDA | -30.88M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.58 |
Balance Sheet
The company has $23.77M in cash and $2.39M in debt, giving a net cash position of $21.38M.
| Cash & Cash Equivalents | 23.77M |
| Total Debt | 2.39M |
| Net Cash | 21.38M |
| Retained Earnings | -513.21M |
| Total Assets | 93.76M |
| Working Capital | 85.20M |
Cash Flow
In the last 12 months, operating cash flow was -$26.77M and capital expenditures -$613.00K, giving a free cash flow of -$27.38M.
| Operating Cash Flow | -26.77M |
| Capital Expenditures | -613.00K |
| Free Cash Flow | -27.38M |
| FCF Per Share | -1.44 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RGLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -100% |
| FCF Yield | -26.37% |
Analyst Forecast
The average price target for RGLS is $7, which is 343% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 343% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Jun 29, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 29, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 0.51 |
| Piotroski F-Score | 3 |